Granulocyte colony-stimulating factor and severe aplastic anemia [1]

Blood

Volumn 109, Issue 10, 2007, Pages 4589-

  Alter, Blanche P ^a   Rosenberg, Philip S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APLASTIC ANEMIA; DISEASE SEVERITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT;

EID: 34248327540     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-068866     Document Type: Letter

References (6)

1. 1. Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2007;109:2794-2796.
2. Young NS. G-CSF and monosomy 7 in marrow failure patients. Blood. 2002;100:741.
3. Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100:786-790.
4. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009-1013.
5. Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol. 1998;103:297-303.
6. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving longterm G-CSF therapy. Blood. 2006;107:4628-4635